Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Current Deferred Revenue (2023 - 2025)

Metagenomi (MGX) has disclosed Current Deferred Revenue for 3 consecutive years, with $8.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue fell 61.78% to $8.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.7 million, a 61.78% decrease, with the full-year FY2025 number at $8.7 million, down 61.78% from a year prior.
  • Current Deferred Revenue was $8.7 million for Q4 2025 at Metagenomi, down from $12.9 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $48.3 million in Q1 2024 to a low of $8.7 million in Q4 2025.
  • A 3-year average of $27.5 million and a median of $25.5 million in 2025 define the central range for Current Deferred Revenue.
  • Biggest YoY gain for Current Deferred Revenue was 42.56% in 2025; the steepest drop was 61.78% in 2025.
  • Metagenomi's Current Deferred Revenue stood at $48.1 million in 2023, then crashed by 52.65% to $22.8 million in 2024, then tumbled by 61.78% to $8.7 million in 2025.
  • Per Business Quant, the three most recent readings for MGX's Current Deferred Revenue are $8.7 million (Q4 2025), $12.9 million (Q3 2025), and $18.9 million (Q2 2025).